Abstract
Acquired drug resistance is a major limitation for successful treatment of cancer. Resistance emerges due to drug exclusion, drug metabolism and alteration of the drug target by mutation or overexpression. Depending on therapy, the type of cancer and its stage, one or several genetic or epigenetic alterations are necessary to confer resistance to treatment. The fundamental question is the following: if a genetically diverse population of replicating cancer cells is subjected to chemotherapy that has the potential to eradicate it, what is the probability of emergence of resistance? Here, we review a general mathematical framework based on multi-type branching processes designed to study the dynamics of escape of replicating organisms from selection pressures. We apply the general model to evolution of resistance of cancer cells and discuss examples for diverse mechanisms of resistance. Our theory shows how to estimate the probability of success for any treatment regimen.
Keywords: Cancer Therapy, Evolution of Resistance, Evolutionary Dynamics
Current Pharmaceutical Design
Title: Evolution of Resistance to Cancer Therapy
Volume: 12 Issue: 3
Author(s): Franziska Michor, Martin A. Nowak and Yoh Iwasa
Affiliation:
Keywords: Cancer Therapy, Evolution of Resistance, Evolutionary Dynamics
Abstract: Acquired drug resistance is a major limitation for successful treatment of cancer. Resistance emerges due to drug exclusion, drug metabolism and alteration of the drug target by mutation or overexpression. Depending on therapy, the type of cancer and its stage, one or several genetic or epigenetic alterations are necessary to confer resistance to treatment. The fundamental question is the following: if a genetically diverse population of replicating cancer cells is subjected to chemotherapy that has the potential to eradicate it, what is the probability of emergence of resistance? Here, we review a general mathematical framework based on multi-type branching processes designed to study the dynamics of escape of replicating organisms from selection pressures. We apply the general model to evolution of resistance of cancer cells and discuss examples for diverse mechanisms of resistance. Our theory shows how to estimate the probability of success for any treatment regimen.
Export Options
About this article
Cite this article as:
Michor Franziska, Nowak A. Martin and Iwasa Yoh, Evolution of Resistance to Cancer Therapy, Current Pharmaceutical Design 2006; 12 (3) . https://dx.doi.org/10.2174/138161206775201956
| DOI https://dx.doi.org/10.2174/138161206775201956 |
Print ISSN 1381-6128 |
| Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
Accelerating Cancer Drug Discovery Using Artificial Intelligence and In Silico Methods
Artificial intelligence and in silico methods speed up cancer drug discovery, transforming how new treatments are developed. Artificial intelligence, along with in silico methods, allows for quick investigation of large biological datasets, helping identify potential drug targets with remarkable speed and accuracy. Machine learning models help us understand how molecules ...read more
Artificial Intelligence and Computational Approaches in Drug Discovery
Computer-aided drug design (CADD) and artificial intelligence (AI) are fundamentally reshaping drug discovery pipelines by significantly enhancing efficiency in molecular screening, rational drug design, and natural product development. In the field of molecular screening, the integration of virtual high-throughput screening with advanced AI models enables rapid analysis of million-compound libraries, ...read more
Artificial Intelligence for Transformative Healthcare: From Prediction to Prevention
Machine learning and deep learning are transforming biomedical diagnosis by allowing for quicker and more accurate disease detection, ultimately enhancing patient care. Using advanced algorithms and extensive medical data, these approaches uncover patterns that may not be visible to humans, resulting in better detection of conditions such as cancer and ...read more
Mapping Dynamic Sites and Designing Novel Therapeutics
The concept of allostery, where ligand binding at a site distinct from the active or orthosteric site modulates protein function, has emerged as a transformative paradigm in modern drug discovery. Unlike conventional orthosteric drugs that often face limitations in selectivity and off-target effects, allosteric modulators offer a promising alternative. Their ...read more
- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Relationships Between the Structural Properties of Flavonoids and their Inhibitory Activities Against Matrix Metallopeptidase 9
Letters in Drug Design & Discovery HSV-1-Derived Recombinant and Amplicon Vectors for Gene Transfer and Gene Therapy
Current Gene Therapy Structure-Function Relationships of Plasminogen Activator Inhibitor-1 and Its Potential as a Therapeutic Agent
Current Drug Targets SPECT-CT in Radiotherapy Planning, with Main Reference to Patients with Breast Cancer
Current Radiopharmaceuticals New Approaches to Photodynamic Therapy from Types I, II and III to Type IV Using One or More Photons
Anti-Cancer Agents in Medicinal Chemistry Meet Our Editorial Board Member
Anti-Cancer Agents in Medicinal Chemistry Delivery of Peptidic Gonadotropin Releasing Hormone Antagonists
Current Drug Delivery Recent Developments Towards Podophyllotoxin Congeners as Potential Apoptosis Inducers
Anti-Cancer Agents in Medicinal Chemistry A Safe and Novel Desensitization Protocol with Ferric Carboxymaltose to Treat Iron Deficiency Anemia
Current Drug Safety Circulating Tumor Stem Cells as Biomarkers for Cancer Progression
Recent Patents on Biomarkers Novel Series of Coumarinyl Substituted-thiazolidin-2,4-dione Analogs as Anticancer Agents: Design, Synthesis, Spectral Studies and Cytotoxicity Evaluation
Anti-Cancer Agents in Medicinal Chemistry Advances in Nanomaterials for Diagnosis and Therapy of Leukemia
Recent Patents on Nanomedicine Small Peptides as Modulators of Serine Proteases
Current Medicinal Chemistry The 21st Century Form of Vitamin E - Tocotrienol
Current Pharmaceutical Design Study of Anti-Renal Cancer Ingredients in Scutellaria barbata on Hollow Fibre Cell Fishing and Hollow Fibre Liquid Phase Microextraction
Current Pharmaceutical Analysis Galectins: Major Signaling Modulators Inside and Outside the Cell
Current Molecular Medicine Synthesis of Metronidazole Derivatives Containing Pyridine Ring and Anticancer Activity
Letters in Organic Chemistry Cell Culture in Microfluidic Systems
Micro and Nanosystems Phosphodiesterase 4 Inhibitors in Inflammatory Bowel Disease: A Comprehensive Review
Current Pharmaceutical Design Cytotoxic and Antibacterial Properties of Resveratrol Oligomers from the Stem Bark of <i>Dryobalanops rappa</i>
The Natural Products Journal





